Contineum Therapeutics develops oral small molecule therapies for neuroscience, inflammation, and immunology indications by targeting specific biological pathways linked to clinical disabilities. Its lead program PIPE 307 is advancing in collaboration with Johnson & Johnson Innovative Medicines, while discovery efforts continue for other NI I targets; the therapies are designed to be taken orally and modulate disease pathways to impact progression. The company differentiates itself through its focused NI I pipeline and strategic partnership with a major pharmaceutical company to support development and potential commercialization. Its goal is to bring effective, pathway-targeted treatments to patients with few options by advancing PIPE 307 through clinical and regulatory milestones and expanding its pipeline via collaborations.
Company Size
51-200
Company Stage
N/A
Total Funding
N/A
Headquarters
San Diego, California
Founded
2017
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?